Login to Your Account

As EPO Hammer Looms

Amgen's Ilypsa Buy: $420M Gets Phase II CKD Therapy

By Randall Osborne

Wednesday, June 6, 2007
Amgen Inc.'s plan to buy out nephrology-focused Ilypsa Inc. for $420 million - thereby gaining a Phase II phosphate binder for chronic kidney disease - put little immediate fear into backers of Genzyme Corp., thanks to progress with the latter's CKD therapy Renvela. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription